VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2017 | Ibrutinib treatment and its associated risk factors

Ibrutinib is associated with a range of side effects, including increased bruising, TKI ecchymosis, low-grade bleeding and hemorrhage. This has led to further studies attempting to clarify the risks of ibrutinib. Here, Jennifer Brown, MD, PhD, from the Dana-Farber Cancer Institute, Boston, MA, provides us with an overview of the results of an analysis of the incidence and risk factors for adverse events in patients treated with ibrutinib. The four randomized trials analyzed included three chronic lymphocytic leukemia (CLL) trials and a mantle cell lymphoma (MCL) trial. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter